Loading
Life sciences · Journal article
European Heart Journal · July 8, 2026
A consensus or society position rather than new primary data.
This is a narrative expert statement articulating health equity as an urgent scientific frontier in cardiovascular medicine, documenting substantial disparities in CVD mortality, risk factor prevalence, and access to care across geography, race, socioeconomic status, and other dimensions globally. The authors present epidemiological evidence of the burden and call for evidence-based interventions to close health equity gaps, but do not report original trial data or intervention efficacy.
Journal article. Global populations, with emphasis on disparities in the United States, Europe, low- and middle-income countries, Brazil, India, New Zealand, and among specific groups defined by race, ethnicity, rurality, socioeconomic status, disability, LGBTQIA+ status, and sex/gender.
CVD remains the leading cause of global death, responsible for 20.5 million deaths annually, with more than 80% occurring in low- and middle-income countries and one-third occurring prematurely In the United States, nearly 50% of the population is at risk for or experiences notable CVD inequities by race, ethnicity, rurality, disability, LGBTQIA+ status, literacy, or socioeconomic status In Europe, health inequities contribute to approximately 700,000 excess deaths annually and over 30 million people experiencing health inequity, accounting for 20% of total health care costs and an estimated negative economic impact exceeding 9% of total GDP
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This statement positions health equity as a core scientific discipline in cardiovascular medicine and calls on clinicians and researchers to move beyond recognizing disparities to developing and implementing evidence-based interventions. The scale of burden—affecting nearly half the US population and generating substantial economic loss—suggests health equity merits integration into clinical practice, research funding, and policy at all levels.
A narrative review and expert consensus statement on health equity in cardiovascular medicine that synthesizes epidemiological data and calls for a new scientific and implementation approach, but does not report original trial results or new empirical evidence.
Quoted from the source exactly as published.
This statement positions health equity as a core scientific discipline in cardiovascular medicine and calls on clinicians and researchers to move beyond recognizing disparities to developing and implementing evidence-based interventions. The scale of burden—affecting nearly half the US population and generating substantial economic loss—suggests health equity merits integration into clinical practice, research funding, and policy at all levels.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
“Health Equity is the absence of unfair, avoidable or remediable differences among groups of people, whether those groups are defined socially, economically, demographically, or geographically or by other dimensions of inequality (eg, sex, gender, ethnicity, disability, or sexual orientation).” The story of cardiovascular medicine is one of extraordinary progress. Remarkable breakthroughs in cardiovascular science and compelling clinical trial data now offer markedly improved outcomes for patients with cardiovascular disease (CVD). Correspondingly, deaths caused by CVD, while still the leading cause of overall mortality, are 50% less over recent decades.1 Moreover, the arsenal for CVD prevention and the mitigation of risk represents a robustly populated and decidedly efficacious armamentarium. On the precipice of discovery and implementation are gene therapy, new biological therapies (eg, therapeutic nucleic acids, gene editing, incretin therapies, and myosin modulators), and the still untapped potential of artificial intelligence and precision medicine in CV care. Yet, this remarkable progress conceals a persistent and troubling truth: not everyone has benefited fairly. Health inequities as defined by the World Health Organization remain an existential challenge in cardiovascular medicine. Despite the scientific triumphs of our field, life expectancy and CVD mortality vary profoundly by geography, race, sex, socioeconomic status, and access to care. Globally, CVD remains the leading cause of death, responsible for 20.5 million deaths annually, with more than 80% occurring in low- and middle-income countries (LMICs) and one-third occurring prematurely. Even within high-income nations, marginalized populations, including rural communities, continue to experience disproportionate disease burden and poorer outcomes akin to outcomes in LMICs. This paradox is no longer tenable and demands a new and different response—one grounded in science. It calls for moving beyond description to action, beyond recognizing inequities to elucidating biology, and beyond rhetorical statements to evidence-based interventions that can meaningfully close the gap. Health equity should be viewed not as a politicized agenda but as a scientific frontier (like any other) in cardiovascular medicine. And, as such, health equity merits consideration as an emerging discipline that integrates data science, translational research, and implementation strategies offering novel solutions with the potential to measurably close the gap. Within the United States, multiple populations experience CVD health inequities by race, ethnicity, rurality, disability, LGBTQIA+, lower literacy levels, and lower socioeconomic status. In the aggregate, nearly 50% of the U.S. population is at risk for or experience notable CVD inequities.2,3 In Europe, recent analyses from the European Society of Cardiology Atlas of Cardiology4 confirm substantial and persisting cardiovascular inequities across and within countries, with pronounced East-West and North-South gradients in CVD mortality, risk factor prevalence, and access to prevention and specialist care. Socioeconomically deprived communities, migrants, and rural populations experience higher disease burden, underuse of guideline-directed therapy, and greater exposure to environmental stressors such as air pollution, noise, and heat. These inequities contribute to approximately 700,000 excess deaths annually and over 30 million experiencing health inequity, imposing large macroeconomic losses across EU Member States.4,5 Thus, this burden accounts for 20% of total health care costs, 15% of social services benefits, and an estimated negative economic impact in the EU >9% of total GDP.6 In the Middle East (and elsewhere), women remain less likely to receive guideline-directed therapy, with worse outcomes—a pattern seen globally. The global toll is staggering. In LMICs, where access to preventive care, diagnostics, and essential medicines is limited, the probability of dying prematurely from CVD is nearly twice that in high-income nations. Inequities are not only measured in mortality but in lost productivity, economic strain, and social destabilization. The World Bank estimates that the economic cost of noncommunicable diseases, driven largely by CVD, could surpass $47 trillion by 2030—an unsustainable trajectory for global development and a morally unconscionable state of health inequity6 (Table 1). The Consequences of Health Inequity and Cardiovascular Disease Disparities Life expectancy varies by nearly 13 y between wealthy areas and favelasa Infant mortality rates 5 times higher in favelas Total socioeconomic burden: GDP 4.1%; $77 billion 700,000 excess deaths/y attributed to health inequities 19% higher odds of prevalent CVD for lower SES households €980 billion/y excess health care spending GDP reduction of 1.4%/y in lost labor productivity Increased infant and under-5 mortality rates in Scheduled Casteb 7.5-y life expectancy differential for rich vs poor Upper Caste Indian women live 15 y longer than in Scheduled Caste Medical poverty increased from 32.5 to 55 million from 2000-2017 The economic loss caused by lost output from premature deaths and morbidity attributable to adolescents at USD 38.01 billion is significantly high in India, equivalent to 1.30% of India’s GDP in 2021. Premature deaths accounted for nearly one-fourth and noncommunicable diseases accounted for nearly 70% of the total economic loss in India. Māoric adults experienced 2 times the age-standardized amenable mortality rate of non-Māori Health inequities between Māori and non-Māori adults cost NZ$828.8 million/y 74,000 excess deaths/y (Black or African Americans) 40% higher prevalence heart disease and 30% increased risk of stroke (rural Americans) $320 billion/y excess health care spending $42 billion/y labor productivity cost aFavelas: shanty towns in Brazil. bSchedule Caste: also known as “Dalits,” the most disadvant
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.